Browsing by Author TAN SHAO PENG, DAVID

Showing results 1 to 11 of 11
Issue DateTitleAuthor(s)
1-Aug-2020A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)Ngoi, Natalie YL; Heong, Valerie; Ow, Samuel ; Chay, Wen Yee ; Kim, Hee Seung; Choi, Chel Hun; Goss, Geraldine; Goh, Jeffrey C; Tai, Bee Choo ; Lim, Diana G ; Kaliaperumal, Nivashini; Au, Veonice B; Connolly, John E ; Kim, Jae-Weon; Friedlander, Michael; Kim, Kidong; Tan, David SP 
2016A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI#9041)Chiu, J.W; Hotte, S.J; Kollmannsberger, C.K; Renouf, D.J; Cescon, D.W; Hedley, D; Chow, S; Moscow, J; Chen, Z; Perry, M; Diaz-Padilla, I; Tan, D ; Hirte, H; McWhirter, E; Chen, H; Siu, L.L; Bedard, P.L
2020A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)Lee, Yong Jae; Lim, Myong Cheol; Kim, Byoung-Gie; Ngoi, Natalie YL ; Choi, Chel Hun; Park, Sang-Yoon; Tan, David SP ; Go, Yunjung; Lee, Jung-Yun
2018Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancersChan, G.H.J; Ong, P.Y; Low, J.J.H ; Kong, H.L; Ow, S.G.W; Tan, D.S.P ; Lim, Y.W; Lim, S.E; Lee, S.-C
5-Dec-2020Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in SingaporeTan, David SP ; Chan, Jack Junjie ; Hettle, Robert; Ghosh, Wrik; Viswambaram, Amrita; Yu, Cindy Chen
Nov-2019Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in SingaporeTan, DS ; Chan, JJ; Loke, JK; Hettle, R; Ghosh, W; Viswambaram, A; Yu, CC
2015CSIOVDB: A microarray gene expression database of epithelial ovarian cancer subtypeTan, T.Z ; Yang, H ; Ye, J ; Low, J ; Choolani, M ; Peng Tan, D.S ; Thiery, J.-P ; Huang, R.Y.-J 
Mar-2021The systemic treatment of recurrent ovarian cancer revisitedBaert, T; Ferrero, A; Sehouli, J; O'Donnell, DM; González-Martín, A; Joly, F; van der Velden, J; Blecharz, P; Tan, DSP ; Querleu, D; Colombo, N; du Bois, A; Ledermann, JA
2017Understanding resistance mechanisms and expanding the therapeutic utility of PARP inhibitorsLim, J.S.J ; Tan, D.S.P 
2018Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) StudyHeong V.; Syn N.L.; Lee X.W.; Sapari N.S. ; Koh X.Q.; Adam Isa Z.F. ; Sy Lim J.; Lim D. ; Pang B. ; Thian Y.L. ; Ng L.K. ; Wong A.L. ; Soo R.A. ; Yong W.P. ; Chee C.E. ; Lee S.-C., Goh B.-C. ; Soong R. ; Tan D.S.P. 
2020Whole exome sequencing of multi-regional biopsies from metastatic lesions to evaluate actionable truncal mutations using a single-pass percutaneous techniqueHeong V.; Tay D.; Goh S.E. ; Wee B. ; Tan T.Z. ; Soo R. ; Pang B. ; Lim D. ; Gopinathan A. ; Ow S. ; Chee C.E. ; Goh B.C. ; Lee S.C. ; Yong W.P. ; Wong A. ; Omar M.F.M. ; Soong R. ; Tan D.S.P.